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Photodynamic killing of cancer 
cells by a Platinum(II) complex with 
cyclometallating ligand
Rachel E. Doherty1, Igor V. Sazanovich1,2,†, Luke K. McKenzie1,2, Alexander S. Stasheuski3, 
Rachel Coyle1, Elizabeth Baggaley2, Sarah Bottomley1, Julia A. Weinstein2 & Helen E. Bryant1
Photodynamic therapy that uses photosensitizers which only become toxic upon light-irradiation 
provides a strong alternative to conventional cancer treatment due to its ability to selectively target 
tumour material without affecting healthy tissue. Transition metal complexes are highly promising 
PDT agents due to intense visible light absorption, yet the majority are toxic even without light. This 
study introduces a small, photostable, charge-neutral platinum-based compound, Pt(II) 2,6-dipyrido-
4-methyl-benzenechloride, complex 1, as a photosensitizer, which works under visible light. Activation 
of the new photosensitizer at low concentrations (0.1–1 μM) by comparatively low dose of 405 nm 
light (3.6 J cm−2) causes significant cell death of cervical, colorectal and bladder cancer cell lines, and, 
importantly, a cisplatin resistant cell line EJ-R. The photo-index of the complex is 8. We demonstrate 
that complex 1 induces irreversible DNA single strand breaks following irradiation, and that oxygen 
is essential for the photoinduced action. Neither light, nor compound alone led to cell death. The 
key advantages of the new drug include a remarkably fast accumulation time (diffusion-controlled, 
minutes), and photostability. This study demonstrates a highly promising new agent for photodynamic 
therapy, and attracts attention to photostable metal complexes as viable alternatives to conventional 
chemotherapeutics, such as cisplatin.
Over 10.9 million people are diagnosed with cancer worldwide every year1. The current treatment options for 
patients include surgery, chemotherapy and radiotherapy. However surgical intervention is not always possible 
and existing chemotherapies, whilst highly effective in many cases, especially with targeted delivery, still often 
cause high levels of non-cancerous cell death and associated toxicity. Whilst enormous progress has been made in 
this area, less invasive and more tumour specific therapies are in continuous need.
A long known and currently re-emerging concept for cancer treatment is the use of light-activated chemother-
apeutics, a process termed photodynamic therapy (PDT)2–6.
PDT is based on the use of compounds which are only toxic to cells following exposure to a specific wave-
length of light. The necessity for light activation allows the tumour mass to be specifically targeted whilst the drug 
remains inert elsewhere in healthy tissue which has not been exposed to light. This approach significantly reduces 
toxicity in healthy tissues7,8.
Photosensitizers are broadly classified into three groups, according to their mechanism of action. In all cases, 
the primary act is absorption of light by the photosensitizer (PS), populating its singlet excited state, 1PS*. Type 
I and type II are two classes of mechanism of ROS/singlet oxygen generation, in both, PDT is initiated by an 
interaction of the photosensitizer in its excited state with oxygen, with the production of reactive oxygen species 
(ROS) including superoxide anion (O2•–), hydroxyl radical (OH• ), or hydrogen peroxide (H2O2), in type I, or 
singlet oxygen (type II), which then induce the damage leading to cell death9,10. In the third class of mechanism of 
photo-activated cell death, which can be referred to as Photo-activated Chemotherapy (PACT), killing is initiated 
by a direct reaction of the photosensitizer in the excited state (or of products of its light-induced transformation) 
with biomolecules, leading to cell death that is independent of oxygen11.
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Oxygen dependent mechanisms rely on the interaction of the excited state of the sensitizer with oxygen. 
Therefore, the compounds with longer-lived excited states are required to maximize the yield of the primary step 
in the therapy. Transition metal complexes are particularly promising in this regard for two main reasons. Firstly, 
this class of compounds usually absorb visible (and in some cases NIR) light strongly. Secondly, the singlet excited 
(S1) populated upon absorption of light (S0 → S1) efficiently populates the triplet excited state (T1), via intersys-
tem crossing, due to strong spin-orbit coupling promoted by the heavy metal atom12. Because of spin-forbidden 
nature of T1 → S0 transition, T1 triplet excited states are significantly longer-lived (microseconds) than singlet 
excited states of organic compounds (S1 → S0), which typically decay within a few nanoseconds.
Recently, several examples of transition metal complexes as either oxygen dependent or independent pho-
tosensitizers in PDT have been reported, including Ru(II), Re(I) and Pt(IV)9,13–28. Here, we demonstrate the 
potential of a small, low-weight Pt(II) complex for PDT. We have previously reported Pt(II)-based compounds of 
dipyridobenzene and derivatives, which intensely absorb light in UV/visible region, possess triplet excited state 
with remarkably long (microseconds) lifetime29,30, and produce singlet oxygen in 70–80% yield in organic solvents 
such as dichloromethane, these reports included complex 1 (previously abbreviated as [PtL3Cl]). Furthermore, 
the compounds are readily taken up by mammalian cells, predominantly residing in the nuclear compartment. 
Such a favorable combination of properties prompted our investigation of this class of compounds as potential 
PDT agents.
The present study demonstrates the light-specific cell toxicity of a representative Pt(II) compound bearing 
cyclometallating dipyrido-benzene type ligand - complex 1 (Fig. 1A) in a range of cancer cells including a cispla-
tin resistant line, and investigates its interaction with DNA and the type of DNA damage induced in cancer cells 
by this new photosensitizer. We note that complex 1 was abbreviated [PtL3Cl] in our earlier reports29,30.
Results
Photodynamic killing of cancer cells by complex 1. We have previously described the use of complex 
1 (Fig. 1A) as an emission imaging agent, where experiments were performed over the course of hours follow-
ing a 5 min incubation time. Within the 24 h window required for imaging, the toxicity established by MTT 
assay was negligible29. In the present study investigations of long term dark and light-induced toxicity have been 
undertaken. complex 1 was added to cells, followed by exposure to 405 nm light (3.6 J cm−2) and cellular viability 
Figure 1. Photodynamic killing of cancer cells by complex 1. (A) Structure of complex 1. (B) Survival 
fractions of HeLa cells following exposure to increasing doses of complex 1. Cells were pre-treated with complex 
1 prior to 3 min exposure to 405 nm light (3.6 J cm−2). (C) Survival fractions of HeLa cells exposed to light in 
the absence of complex 1. (D) Survival fractions of cervical cancer (HeLa), colorectal cancer (SW480), bladder 
cancer (EJ) and cisplatin-resistant bladder cancer (EJ-R) cells. Cells were pre-treated with 400 nM complex 1 
prior to 3 min exposure to 405 nm light. Data shown are mean and standard deviation of at least 3 independent 
experiments. Significance was determined using the Student’s T-test where n = 3 and p < 0.01 is indicated by **, 
and p < 0.05 is indicated by *. Survival fractions were calculated relative to untreated control.
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examined at several time-points up to 12 days post exposure. Figure 1B demonstrates the cytotoxic effect of com-
plex 1 with and without exposure to light in the human cancer cell line HeLa. The data demonstrate a significant 
increase in the toxicity of complex 1 following exposure to light at a complex 1 concentration as low as 0.1 μM. 
Furthermore, complex 1 without exposure to light remains non-toxic to cells up to a dose of 1 μM. LD50 values 
in HeLa cells are 0.2 μM in light and 1.6 μM in dark, making the photo-index of this complex 8. There was no 
significant cell death following exposure to light alone (Fig. 1C).
Similar light-induced toxicity of complex 1 with low-level toxicity in the dark has been observed in two fur-
ther cancer cell lines, the colorectal cancer cell line SW480 and the bladder cancer cell line EJ (Fig. 1D): in each 
case exposure to light caused complex 1-induced cell death. Moreover, light-induced complex 1-mediated cell 
death occurred in the cisplatin-resistant bladder cancer cell line EJ-R (Fig. 1D), thus suggesting that it could be an 
alternative therapy for cancers which are resistant to current platinum-based drugs. The light specific cell death 
demonstrated here and the low dark toxicity of complex 1 highlights its potential as an appropriate PDT agent.
Complex 1 binding to DNA. Complex 1 has been shown to accumulate within the nucleus of cells29 and 
the planar coordination, polycyclic structure and aromaticity of the compound suggest that some degree of DNA 
intercalation is likely. We therefore investigated the ability of complex 1 to bind DNA in cells. Cells were incu-
bated with complex 1 for 30 min, chromosome metaphase spreads were prepared and imaged using multiphoton 
excitation (λ ex = 780 nm) (Fig. 2A). Chromosomes were stained with complex 1 indicating that nuclear local-
ization is due at least in part to accumulation in DNA. The mode of DNA binding was then examined. In the 
presence of calf thymus DNA in solution, the emission decay of complex 1 can be described as biexponential, 
with the lifetimes of 3 (± 0.5) μs, and 11(± 0.5) μs (Fig. 2B). The 11 μs value is close to the radiative lifetime of the 
excited state of complex 129, and indicates some protection from oxygen, most likely though intercalation31,32. The 
presence of a 3 μs decay component, which is still considerably longer than the anticipated lifetime for complex 
1 emission (< 1 μs) in an air-equilibrated media, suggests that an additional mode of binding exists, most likely 
groove binding. We speculate these binding modes may allow some limited access of oxygen to complex 1 which 
would cause partial quenching of the triplet excited state.
To further support the hypothesis that complex 1 interacts with DNA we demonstrated its ability to com-
petitively bind to DNA versus the known DNA intercalator Ethidium Bromide (EtBr). Figure 2C shows that 
increasing the concentration of complex 1 correlates with an increase in displacement of EtBr bound to DNA 
into solution, therefore demonstrating complex 1 is able to intercalate into DNA in the same manner as EtBr. 
Assuming a binding constant of 1.0 × 107 M−1 for EtBr33, the binding constant determined for complex 1 by this 
method is 1.19 (± 0.08) 105 M−1. Significantly adduct formation with G-N7 position of DNA was tested and found 
to be negative (supporting information S4).
Light-activated complex 1 induces DNA single strand breaks (nicks) in plasmid DNA. Having 
established light-induced cell killing by complex 1, the next step was to determine whether complex 1 induces 
DNA damage, and if so whether such damage is light dependent. Therefore plasmid DNA was incubated with 
increasing concentrations of complex 1, followed by irradiation with 405 nm light; a parallel experiment without 
irradiation was performed in each case. The presence of single strand breaks (SSBs) in DNA was determined by 
agarose gel electrophoresis (Fig. 3). Circular plasmid DNA which has had a SSB introduced loses its supercoiled 
shape and therefore is unable to migrate as far through an agarose gel as more compact supercoiled DNA, such 
DNA is often termed “nicked” DNA. In this way, the presence of a second band at a higher weight in an agarose 
gel indicates the presence of nicked DNA i.e. SSBs in a sample (control lane 2). Figure 3 clearly demonstrates 
that complex 1 induces DNA SSBs only after light activation. Neither complex 1 nor light alone were sufficient to 
induce DNA SSBs. Furthermore the DNA nicking effect of light-activated complex 1 was concentration depend-
ent, with the largest increase in nicked DNA being present at the highest concentration of 1 μM (Fig. 3B). The 
absence of induction of the linear form of plasmid of DNA (seen as an intermediate migrating band - linear con-
trol lane 3), suggests that light-activated complex 1 does not induce double strand breaks in DNA.
Addition of EtBr into the reaction reduced induction of SSBs in plasmid DNA (Fig. 3C), suggesting that 
in vitro light-activated DNA damage by complex 1 is dependent upon a mode of complex 1-DNA binding which 
is inhibited by the presence of EtBr. In addition performing the reaction in the absence of oxygen (hypoxic condi-
tions) prevented induction of SSBs (Fig. 3D) demonstrating that complex 1-induced breaks are dependent upon 
oxygen. Taken together these data suggest that breaks are induced when light activated complex 1 is bound to 
DNA in a binding mode in which complex 1 has access to oxygen.
Light-activated complex 1 induces single strand DNA breaks in cancer cells. In order to deter-
mine whether complex 1 is also capable of inducing DNA damage within cells upon irradiation with light, a neu-
tral COMET assay was used. This assay enables the detection of both DSBs and SSBs in DNA within individual 
cells34, by lysing cells and then performing single cell electrophoresis - any damaged DNA migrates out of the cell 
as a ‘tail’ (Fig. 4A). Four treatment groups were set up, DMSO control, complex 1 alone, DMSO with light, and 
complex 1 with light. Cells from each group were harvested for analysis of DNA breaks at several time points up 
to 24 h post treatment. The results show a large number of DNA breaks induced immediately following complex 1 
and light treatment (Fig. 4B), the majority of this damage was not repaired 24 h post treatment. Significantly lower 
levels of DNA damage were observed in cells treated with complex 1 or light alone.
The COMET assay is not able to distinguish between DSBs and SSBs in DNA and therefore pulsed field gel 
electrophoresis (PFGE) was performed on cells immediately following complex 1 and light treatment (Fig. 4C). 
PFGE only detects DSBs in DNA35, it is not able to detect SSBs, in this way we were able to determine whether 
the breaks observed in the COMET assay were either SSBs or DSBs. Gamma irradiated cells were used as positive 
control for DSBs in DNA. Figure 4C clearly demonstrates the absence of DSBs in treated cells, confirming the 
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DNA breaks observed in treated cells using the COMET assay protocol are indeed SSBs and not DSBs. This result 
supports the observations from plasmid DNA that SSBs not DSBs are induced by light-activated complex 1. As 
unrepaired DNA strand breaks are known to cause cell death36, these data strongly suggest that the light-induced 
complex 1-mediated specific killing of cancer cells observed in Fig. 1 is caused by the induction of DNA breaks 
which are unable to be repaired in cells.
Figure 2. Complex 1 binding to DNA. (A) Metaphase spread of chromosomes extracted from HeLa cells 
that had been pre-incubated with complex 1. Emission image (left); light microscope image (right) and 
merged image (centre). (Bi) Emission decay of complex 1 recorded at 525 – 575 nm range as a function of 
concentrations of calf thymus DNA under 410 nm pulsed excitation. (Bii) Relative amplitudes of the emission 
decay component attributed to the unbound -◾-, intercalated -◽-, and partially intercalated -⬨ - [complex 1] at 
different DNA concentrations. –x- is a sum of the relative contribution of the two DNA-bound forms, -⬨ - and 
-◽-. (C) Competitive DNA binding of complex 1 versus EtBr.25 μM calf thymus DNA was incubated with 10 μM 
EtBr, followed by titration with complex 1 solution. The emission spectrum of the displaced EtBr has been 
measured. (Ci) Increase in relative emission intensity of free EtBr upon addition of [complex 1] to the DNA 
pretreated with EtBr. (Cii) Emission spectra from which the data in Ci were obtained. The inset shows the plot 
used to determine the binding constant, see text for details.
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Discussion and Conclusions
The results presented above can be summarized as follows. In several cancer cell models complex 1 has been 
demonstrated to behave as a promising photosensitizer under visible light (405 nm light, light dose 3.6 J cm−2). 
The typical light dose range used in PDT with small metal complexes is ~2–30 J cm−2, demonstrating that com-
plex 1-induced photosensitizion can be caused by comparatively low doses of light13,16,21–24,26. The LD50 values 
for complex 1 in HeLa cells are 0.2 μM with light and 1.6 μM without, giving a photo-index of 8. It is worth noting 
that while other compounds have been shown to have values of up to 3 magnitudes higher22,23, many other small 
metal complexes are reported with similar photo-indexes of < 1016,17,21,26.
Both light or compound alone induced a low level of DNA strand breaks which are quickly repaired in cells. 
However in the presence of light and complex 1 a large number of DNA strand breaks are induced; these breaks 
are not fully repaired by 24 h post induction, a time frame under which one would expect to see repair37. In 
circular DNA in solution, addition of EtBr as well as using hypoxic conditions prevented DNA break induction, 
indicating that breaks are dependent both on complex 1-DNA binding and on the presence of oxygen for their 
formation. This suggests that breaks are the result of ROS/singlet oxygen creation upon light mediated activation 
of DNA bound complex 1.
In apparent contradiction to these data, while complex 1 photosensitizes singlet oxygen efficiently (70%)29 in 
organic solvents, in the presence of DNA in H2O, no singlet oxygen was detected within 5% limit of the equip-
ment used (see36 for method description), which is consistent with the majority of the complex being fully pro-
tected from oxygen. However these in vitro data do not exclude the possibility that in cells a portion of DNA 
Figure 3. Light-induced activation of complex 1 induces DNA single strand breaks (DNA nicks) in plasmid 
DNA and is inhibited by addition of ethidium bromide or in hypoxic conditions. (A) Electrophoresis of 
PUC19 plasmid DNA treated with (+ ) and without (− ) 405 nm light (3.6 J cm−2) and between 0 μM and  
1 μM of complex 1. 0.3 μg DNA was loaded from each sample. Lanes 1–3 represent control DNAs where nicks/
single strand breaks were induced by rapid freeze thawing of DNA and linearization induced using a restriction 
endonuclease. (B) Quantification of the light-induced change in ratio of nicked to supercoiled DNA. Values 
represent fold increase in ratios in light exposed compared to non-exposed samples. (C) Quantification of the 
light-induced change in ratio of nicked to supercoiled DNA when ethidium bromide (EtBr) was included in the 
reaction. (D) Quantification of the light-induced change in ratio of nicked to supercoiled DNA when reactions 
were carried out under normoxic or under hypoxic (0.1% oxygen) conditions. Data shown are mean and 
standard deviation of at least 3 independent experiments. Significance was determined using the Student’s T-test 
where n = 3 and p < 0.05 is indicated by *.
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bound complex 1 can generate sufficient singlet oxygen or other ROS in the presence of light to induce DNA SSBs 
and cause cell killing.
It has been stated above that complex 1 interacts with the DNA via at least two different mechanisms. An emis-
sion lifetime of 11 μs (which is close to the radiative lifetime for this compound at room temperature), together 
with the substitution studies using EtBr indicate one of the modes of complex 1–DNA interaction is likely to be 
intercalation or at least partial intercalation. This mode of DNA interaction, is documented for other transition 
metal complexes with planar structures similar to complex 138. Intercalation is expected to give complete pro-
tection from oxygen, while partial intercalation would allow for creation of ROS/singlet oxygen molecules upon 
light mediated activation of complex 1. An additional different mechanism of binding of complex 1 to DNA 
is indicated by the emission lifetime component of up to 3 μS. This value is less than the radiative lifetime, but 
larger than the emission lifetime observed in an air-saturated solution of complex 1, and is indicative of a partial 
protection from oxygen. We speculate that this effect is due to external binding, perhaps to the minor groove of 
DNA, which could also allow for creation of ROS/singlet oxygen molecules upon light mediated activation of 
complex 1. Thus while data with circular DNA demonstrates that DNA binding and oxygen are both required 
for induction of DNA SSBs and data generated in complex 1 treated cells suggest that it is irreversible DNA SSBs 
that are responsible for killing cells, it is not clear which of the two modes of DNA binding detected in solution is 
occurring in cells and is responsible for DNA SSBs or cell killing.
Several routes of photosensitization action of complex 1 can be speculated upon. Firstly, it is possible that in 
the presence of oxygen light itself induces damage to DNA which under usual circumstances are repaired through 
the existing cellular mechanisms. However, in the presence of complex 1, these mechanisms are compromised, 
leading to irreversible damage. Secondly, it is possible that complex 1 engages in photoinduced electron transfer 
with one of the DNA bases, creating a radical-ion of the base, which then propagates the damage. Thirdly, it is 
possible that non-intercalated or partially-intercalated DNA bound complex 1 is not fully protected from oxygen, 
and is engaged either in the production of singlet oxygen (< 5% yield may still be sufficient to initiate the process) 
or other ROS, which cause DNA single strand breaks. Each of these mechanisms assumes that it is damage of 
DNA that causes cell death, however it should also be remembered that complex 1 is localized throughout the 
nucleus and to a lesser extent the cytoplasm, therefore it is possible that non-DNA bound forms of the drug when 
activated by light are killing cells. The discussion of possible routes of action highlights the complexity of inter-
preting in vitro data when determining the mechanism of action of photosensitization in cells.
Figure 4. Light-induced complex 1 activity selectively induces DNA single strand breaks within cells. (A) 
Representative COMET assay images for each of the treatments. Images were obtained using the full spectrum 
function of the CometScore™ computer software. Cells were originally stained with SYBR Safe™ DNA gel stain. 
(B) Average Tail Moment (TM) in HeLa cells at various time points following treatment with 0.5 μM complex 
1 with and without exposure to 405 nm light (3.6 J cm−2). The average TM was calculated using CometScore™ 
software, where at least 50 cells were analysed on each of 3 occasions and the standard deviation is shown. 
(C) Pulsed-field gel electrophoresis to visualise DSBs in cells treated with 0.5 μM complex 1 with and without 
exposure to 405 nm light. Cells were harvested immediately after treatment. Gamma irradiation (1 – 5 Gy) of 
cells was used as positive control for the induction of DSBs.
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Although photosensitizers that target DNA could be argued to have the potential to induce mutations in cells, 
targeting of DNA for chemotherapy has long been an established and successful way of treating cancer. As with 
other agents, should this compound be taken forward to the clinic the potential for long-term side effects of ther-
apy need to be weighed up against the increased survival benefit that could be achieved in patients.
Overall, it is clear that complex 1, is a low-weight charge-neutral compound with high chemical- and 
photo-stability29. It is easy to prepare, rapidly penetrates cells, and can act as a photosensitizer in a diverse 
range of cancer cell lines including an example of cis-platin resistant cells. This highlights the potential of small 
light-absorbing metal complexes for PDT applications.
Methods
Compound. Complex 1, Pt(2,6-dipyrido-4-Me-benzene)Cl, was prepared following the procedure described 
previously30 and characterized by NMR spectroscopy, elemental analysis, and high-resolution mass-spectroscopy. 
Analytical data (see Supplementary Figs S1–S3) are consistent with those reported previously. Detailed charac-
terization of absorption and emission properties, singlet oxygen yield, and cellular uptake and localisation, have 
been reported by us previously29,30,39.
Cell culture. The cancer cell lines used, HeLa (cervical), SW480 (colorectal) and EJ (bladder), were purchased 
from American Type Culture Collection. The EJ-R (cisplatin resistant) cell line was generated previously40. All cells 
were cultured in Dulbecco’s modified Eagles Medium (DMEM) with 10% fetal calf serum, penicillin (100 U ml−1) 
and streptomycin (100 μg ml−1) at 37 oC in 5% CO2.
Drug treatment. Complex 1 initially was dissolved in DMSO and stored at stock solutions of 0.05 mM, 
0.5 mM and 5 mM at − 20 °C, then further diluted in cell media for working concentrations which were kept 
upto 1 week at 4 oC. Cells were trypsinised, washed with phosphate buffered saline (PBS) and re-suspended in 
phenol-red free DMEM in a soda glass vial. The re-suspended cells were treated with complex 1 solution, or with 
the same concentration of pure DMSO (vehicle control) and exposed to 405 nm light for 3 minutes (light source: 
M405L2 LED (Thorlabs, Newton, NJ, USA)) focused to 1 × 1 cm2 spot at sample, light power at sample adjusted 
to 20 mW), this equates to 3.6 J cm−2. Complex 1 concentration ranged from 50 nM to 100 μM. Control experi-
ments without exposure to light were performed for each dosage to determine toxicity of DMSO and complex 1 
in the absence of light. The maximum concentration of DMSO in biological experiments was 0.1%. The controls 
contained the same concentration as complex 1 treated samples.
Toxicity assay. Between 2500 and 10,000 cells were treated as described above and subsequently plated onto 
100 mm dishes. Following 10–12 days, when colonies could be observed, dishes were fixed and stained with 4 g/L 
methylene blue in methanol. Colonies consisting of more than 50 cells were then counted and the survival frac-
tions for each dose compared to vehicle control cells were calculated.
DNA cleavage assay. A total of 1.5 μg of PUC19 plasmid DNA was incubated in 50 mM Tris-HCl 18 mM 
NaCl, pH 7.2 buffer with either 0.5 μM complex 1 or DMSO in a total reaction mixture of 125 μl. Reaction mix-
tures were then exposed to light as described above. The control reactions without exposure to light for DMSO 
and 0.5 μM complex 1 were set up in parallel. All reactions were then incubated overnight at 37 °C. 5 μl of 0.05% 
bromophenol blue loading buffer was added to 25 μl of each reaction mixture prior to electrophoresis on a 
1.2% agarose gel run at 100 V for 1 hour. Gels were stained with 1 μg/ml Ethidium Bromide (EtBr) and then 
visualised on a UGenius fluorescence gel imager (Syngene, Cambridge, UK). DNA bands were quantified using 
GelQuantNET software (Biochem lab solutions, San Francisco, Ca, USA). The ratio of nicked DNA versus super-
coiled DNA was determined and then the fold change in that ratio between no light conditions and light condi-
tions at each dosage was calculated. To determine DNA cleavage capacity of complex 1 following intercalation of 
EtBr, 19 μM of PUC19 plasmid DNA base pairs was saturated with 13.1 μM EtBr for 5 minutes prior to addition of 
0.5 μM complex 1. To determine DNA cleavage capacity of complex 1 under hypoxic conditions PUC19 plasmid 
DNA was incubated in an environment containing < 0.1% oxygen in a hypoxic chamber (Don Whitley VA500 
anaerobic workstation fitted with individually gassed humidified boxes (Don Whitley Scientific, Shipley, West 
Yorkshire) for 30 min in the dark prior to light treatment.
Optical spectroscopy experiments. The emission spectra were recorded on Fluoromax 4 spectrofluorim-
eter (HORIBA Jobin Yvon). Emission lifetime measurements were performed on the mini-τ spectrofluorometer 
(Edinburgh Instruments), with 405 nm pulsed diode laser as an excitation source. The emission decays were 
detected in the spectral range 475–525 nm selected by a bandpass filter.
The competitive binding experiments for complex 1 vs. EtBr were performed as described previously41. The 
concentrations of calf thymus DNA were 25 μM DNA base pairs and 10 μM EtBr. The concentrations of added 
complex 1 were in the range of 0 to 75 μM. Calf thymus DNA (sodium salt, Type I, fibers) and EtBr (molecular 
biology grade) were purchased from Sigma Aldrich and used without further purification.
For each sample solution, the emission spectrum of EtBr was recorded under excitation at 513 nm. The 
emission spectrum of free EtBr in buffer without DNA at the same optical density as when bound to DNA was 
recorded and subtracted as background in the data processing. The integrated intensity of EtBr emission was 
plotted vs. concentration ratio of EtBr to complex 1 to obtain the binding constant for complex 1 intercalation 
into DNA.
To verify complex 1 intercalation into DNA, emission titrations of complex 1 solution (15 μM) with calf 
thymus DNA (in the range of 0 to 0.6 mM DNA base pairs) were performed, and the emission spectrum and 
emission decay of complex 1 were recorded as a function of DNA concentration (excitation at 380 nm for emis-
sion spectral measurements and at 405 nm for emission lifetime measurements). All the measurements were 
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performed in quartz fluorimeter cuvettes (Starna Scientific, 1 cm pathlength). The UV-Vis absorption spectra 
were measured on Cary 50 Bio spectrophotometer to adjust sample concentrations and to confirm sample com-
position. All the samples were prepared by mixing appropriate amounts of the corresponding stock solutions. The 
concentrations of stock solutions of complex 1, calf thymus DNA and EtBr were checked spectrophotometrically 
using the known extinction coefficients 6.78 × 103 M−1 cm−1 at 412 nm for complex 129 1.32 × 104 M−1 cm−1 at 
260 nm (per base pair) for calf thymus DNA42 and 5448 M−1 cm−1 at 480 nm for EtBr43. Tris-HCl buffer pH 7.4 
was used in all emission experiments.
COMET assay. COMET assay reagents were purchased from Trevigen and used according to the manufac-
turer’s neutral COMET protocol (Gaithersburg, MD, USA). Briefly, 1 × 106 cells were either treated with DMSO 
or 0.5 μM complex 1 with and without light as described above. 2.5 × 105 cells from each treatment were resus-
pended in 250 μl PBS. The remaining cells in each treatment were split into 3 separate plates and cultured in 
DMEM + 10% FCS to be analysed at 4 h, 8 h and 24 h post treatment. For COMET analysis 25 μl of cell suspension 
was mixed with 250 μl molten LMAgarose and then 75 μl of the mixture pipetted immediately onto COMET 
slides. LMAgarose was allowed to set at 4 °C for 20 minutes and then immersed in chilled lysis buffer for 30 min-
utes at 4 °C. Slides were then subjected to electrophoresis at 20 V for 45 minutes in chilled electrophoresis buffer 
(0.5 M Tris, 1.5 M sodium acetate). Following electrophoresis slides were incubated for 30 min in DNA precipi-
tation solution (5 M ammonium acetate in 95% ethanol) at room temperature and then fixed in 70% ethanol for 
20 min at room temperature. Slides were then allowed to dry and then each sample stained with 50 μl 1 × SYBR 
green before visualisation on a Nikon TE200 inverted fluorescent microscope (Nikon instruments, Kingston, 
UK). For each treatment the average tail moment of between 50 and 100 cells was calculated using the TriTek 
CometScore software (TriTek Corporation, Sumerduck, VA, USA).
Pulse field gel electrophoresis (PFGE). To identify double strand breaks (DSBs) in DNA 1 × 106 cells 
were treated with either DMSO or 0.5 μM complex 1 with and without 405 nm light exposure, as described above. 
Cells were resuspended in 50 μl PBS and mixed with 50 μl InCert agarose (Lonza, Basel, Switzland). The mixture 
was then added to the plug insert and allowed to set at 4 °C for 20 minutes. Plugs were then incubated in 1 ml 
of 0.5 M EDTA, 1% N-laurylsarcosyl, proteinase K (1 mg/ml) buffer for 48 h at room temperature. Following 
incubation, plugs were washed 4 times in TE buffer and then loaded into a 0.7% chromosomal grade agarose 
gel. Separation by pulse field electrophoresis was subsequently performed for 24 h (Biorad; 120o angle, 60–240 s 
switch time, 4 V/cm). After pulse field electrophoresis the gel was stained with EtBr and visualised on a UGenius 
fluorescence gel imager (Syngene, Cambridge, UK).
Metaphase spread. 2 × 106 HeLa cells were incubated with 50 μM complex 1 for 10 min before colcemid 
(1:200 dilution of 10 ug/ml Gibco® KaryoMAX® Colcemid™ ) was added for 90 min. Cells were then trypsinised 
and washed. A solution of 0.075 M KCl and was added for 10 minutes. Cells were washed and fixative (3:1 metha-
nol: acetic acid) was added. Cell solution in fixative was dropped onto moist, clean microscope slides and allowed 
to dry. A coverslip was added using mounting agent (Immu-Mount™ , Thermo Scientific Shandon™ ). Slides were 
imaged using multiphoton excitation (λ ex = 780 nm) on a Zeiss LSM 510 upright microscope.
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